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ABSTRACT 
Improvements in swine diagnostic medicine is a never-ending pursuit.  However, whereas most 
researchers focus on assay improvements, this research focused on developing improvements to 
the sample itself.   
 
The thesis begins with a review of the IgG molecule and the mechanisms and external factors 
that affect its stability in aqueous solutions.  Chapter 2 summarizes the key discoveries that led to 
an understanding of the structure and functionality of antibodies, the main physicochemical 
mechanisms and external factors that affect the stability of IgG in aqueous solutions, the 
implications of IgG stability for diagnostic medicine, and practical recommendations for 
preserving IgG in diagnostic specimens.   
 
Chapter 3 describes an experiment that evaluated the immediate and temporal effects of 
chitosan-based clarification treatments on PRRSV ELISA-detectable IgG in swine oral fluids.  
Serum and OF samples of known status were generated by vaccinating pigs (n = 17) with a 
PRRSV MLV vaccine.  Individual pig oral fluid samples were collected from day post 
vaccination -7 to 42 and then subdivided into 4 aliquots.  Each aliquot was treated with one 
formulation (A, B, C) with the 4th aliquot serving as untreated control.  All samples were tested 
by PRRSV OF ELISA immediately after treatment (day post-treatment DPT 0).  Thereafter, 
samples were held at 4°C and re-tested on DPTs 2, 4, 6, and 14.  Both immediate and temporal 
treatment effects were evaluated for their quantitative (sample-to-positive ratio) and qualitative 
(positive vs negative) effects on the PRRSV oral fluid ELISA results.  Analysis of results 
showed that the chitosan-based swine oral fluid clarification formulations evaluated in the study 
did not affect the stability or diagnostic functionality of PRRSV IgG either immediately after 
treatment or up to 14 days post-treatment, as measured using PRRSV ELISA S/P results.   
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 CHAPTER 1.  THESIS ORGANIZATION 
This thesis is organized in three chapters.  Chapter 1 contains a general introduction to the thesis 
organization.  Chapter 2 is a literature review titled “Stability of IgG in diagnostic specimens – 
Considerations for veterinary diagnosticians” for submission to the Journal of Veterinary 
Diagnostic Investigation.  Chapter 3 is a scientific research paper titled “Effect of chemical 
clarification of oral fluids on the detection of PRRSV IgG” which has been submitted to the 
Journal of Porcine Health Management.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
CHAPTER 2.  STABILITY OF IgG IN DIAGNOSTIC SPECIMENS – 
CONSIDERATIONS FOR VETERINARY DIAGNOSTICIANS 
 
 
Yuly A Henao-Díaz1, Luis Giménez-Lirola,  
Jeffrey J. Zimmerman  
 
 
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary 
Medicine, Iowa State University, Ames, Iowa, USA  50011-1134 
 
1Corresponding Author: Yuly A. Henao-Diaz, Veterinary Medicine Research Institute, College 
of Veterinary Medicine, Iowa State University, Ames, IA  50011-1240. 
 
Running head: IgG stability, considerations for veterinary diagnosticians  
 
For submission to the Journal of Veterinary Diagnostic Investigation 
 
 
Abstract  
The 1890's saw the introduction of agglutination and/or precipitation diagnostic assays for a 
variety of bacterial pathogens of animals and humans, but the foundations of antibody-based 
diagnostic medicine were firmly laid by early 20th century researchers whose work revealed the 
structure and function of the antibody molecule.  In mammals, the IgG is the most important 
antibody in diagnostic medicine because it is highly abundant in serum and is found in nearly 
every conceivable diagnostic specimen, e.g., colostrum, milk, oral fluids, urine, feces, meat 
exudate ("meat juice"), and others.  However, this specialized glycoprotein is susceptible to 
physicochemical and enzymatic processes that affect its structural integrity and diagnostic 
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functionality.  The purpose of this review is to summarize the key events that led to an 
understanding of the structure of antibodies, the mechanisms and external factors that affect the 
stability of antibodies in aqueous solutions (especially IgG), and issues for antibody stability in 
diagnostic specimens.   
 
Key words: IgG; Antibodies; Stability; Functionality; Diagnostic; 
 
 
Introduction 
The purpose of this review is to summarize the key events that led to an understanding of the 
structure of antibodies, the mechanisms and external factors that affect the stability of antibodies 
in aqueous solutions (especially IgG), and the implications of antibody stability for diagnostic 
medicine. 
 
In 1796, Edward Jenner observed that cowpox, a mild disease in humans caused by infection 
with vaccinia virus, seemed to confer protection against smallpox.  This idea was confirmed by 
"vaccination" (Jenner's term) experiments, i.e., intentional exposure of people to vaccinia virus 
(Jenner, 1800).  Nearly a century later, in 1890, Behring and Kitasato (MacNalty, 1954) 
furthered the idea of protection by intentional exposure when they showed that animals became 
resistant to tetanus or diphtheria after vaccination with these inactivated pathogens.  They 
hypothesized that the immunized animal produced “antitoxins” that countered the effect of these 
pathogens, thus causing the vaccinated animal to become resistant to doses fatal to unvaccinated 
animals.  Furthermore, they showed that serum from vaccinates protected non-vaccinates from 
clinical disease, i.e., the protective substances were present in the serum of immunized animals 
(Macnalty, 1954).  The foundations of humoral immunity theory were definitively established in 
1906 when these “antitoxins” were termed “antibody” by Paul Ehrlich in his book Collected 
Studies on Immunity (Ehrlich et al., 1906).  Subsequently, working with immune precipitates 
from horse and rabbit serum, Heidelberger and collaborators determined that antibodies came in 
two principal forms with distinct mass and sedimentation rates, i.e., high (19S) and low (7S) 
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molecular weights.  These same forms are today known as immunoglobulins (Ig) IgM and IgG, 
respectively (Eisen, 2001; Heidelberger and Pedersen, 1937). 
 
As reviewed by Merchant and Packer (1956), the ability of antibodies to agglutinate and/or 
precipitate bacteria was recognized in 1889 and subsequently used to develop laboratory 
diagnostic assays for a variety of bacterial pathogens of humans and animals, e.g., Salmonella 
spp., Brucella spp., Burkholderia mallei, Erysipelothrix rhusiopathiae, and others.  In time, 
portable kits were developed, such as the “rapid agglutination test for the diagnosis of swine 
erysipelas”, described by Schoening and Creech in 1935.   
 
Research on the development of antibody-based assays for viral pathogens was delayed by the 
requirement for reliable cell culture techniques (Shope, 1931), but in 1941, the serendipitous 
observation of red blood cell agglutination by allantoic fluid from chick embryos infected with 
influenza A virus led to the development of the hemagglutination inhibition assay (Hirst, 1941, 
1942).  At about the same time, Coons (1942) used fluorescein-labelled antibody and 
fluorescence microscopy to visualize pneumococcal antigen in tissue sections.   
 
After World War II, antibody-based technology broadened to new formats and expanded beyond 
infectious diseases.  For example, radioimmunoassay (RIA) was described in 1956 and was later 
applied to the quantitation of various targets, e.g., hormones, vitamins, enzymes and others 
(Berson et al., 1956; Yalow and Berson, 1960).  Wide and Porath (1966) subsequently used the 
principles of RIA to develop the enzyme-linked immunosorbent assay (ELISA).  New doors in 
research and diagnostics were opened when Kohler and Milstein (1975) found that monoclonal 
antibodies, i.e., antibodies intentionally created for a pre-defined purpose, could be produced by 
fusing cultured myeloma cells and spleen cells from an immunized mouse.  The first therapeutic 
monoclonal antibody was approved by the U.S. FDA in 1986.  OKT3, a murine monoclonal 
antibody, was able to neutralize mature T-lymphocyte by binding CD3 and was used to treat 
acute organ transplant rejection (Sgro, 1995).  In the following 30 years, new techniques for 
creating monoclonal antibodies were developed, concurrently with the number of FDA-approved 
5 
 
 
 
 
therapeutic monoclonal antibodies, particularly in the areas of oncologic and autoimmune 
diseases (An, 2010; Clementi et al., 2012; Liu, 2014). 
 
Antibody structure and function 
Marrack (1938) hypothesized a common antibody polypeptide structure on the basis of earlier 
work showing similar protein composition in IgG antibodies with different responses to antigens.  
Work by Smith et al. (1955) demonstrating an identical polypeptide sequence among rabbit 
immunoglobulins with different immunological specificities plus later improvements in 
technology, e.g., the automatic amino acids analyzer, ion-exchange chromatography, etc., 
confirmed this hypothesis (Moore et al., 1958).  Workers in the 1960s established methods to 
fragment IgG, described the amino acid composition of antibody structures, and explored their 
functions (Nisonoff et al., 1960; Yamashita et al., 1968).  Finally, in 1977, an understanding of 
the three-dimensional structure of the intact glycoproteic structure of the IgG molecule was 
achieved through X-ray crystallography (Padlan, 1994; Silverton et al., 1977).  
 
As shown in Figure 1, the mammalian antibody is a Y-shaped glycoprotein (Butler et al., 2017; 
Padlan, 1994; Wang et al., 2007).  The end of each arm of the "Y" (Fab or fragment antigen 
binding region) contains the hypervariable region (HV), which defines the specificity of the 
antibody's antigen binding properties (Padlan, 1994).  The base of the "Y" (Fc or fragment 
crystallizable region) in involved in various functions:  activation of complement and 
interactions with specific Fc receptors (FcRs) associated with phagocytosis, cell-mediated 
cytotoxicity, transplacental transport of antibody, and antibody catabolism, (Butler et al., 2017; 
Mimura et al., 2001; Ravetch and Kinet, 1991; Vidarsson et al., 2014).  The Fab and Fc portions 
of the antibody structure are connected by a hinge that allows the molecule to twist and flex 
during interactions with antigens, FcRs, and complement (Cervenak et al., 2009; Mimura et al., 
2001).  The hinge region varies in length among isotypes and species, with increasing in length 
corresponding to an increasing number of amino acids and disulfide bridges (Padlan, 1994).   
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Figure 2.1. Primary or monomeric antibody (IgG) structure.  The heavy chain is formed by 
VH+CH1+CH2+CH3 domains, the light chain is formed by VL+CL domains.  All 
domains include intra-chain disulfide bridges.  Inter-chain disulfide bridges connect 
the light with the heavy chains.  The Fabs and Fc functional portions assemble the 
IgG structure through the hinge region and disulfide bridges. 
 
Greater length results in higher molecular weight, but also a more susceptibility to degradation 
(Lipman, 2005; Wang et al., 2007).   
 
Structurally, the antibody monomer is composed of four chains: two identical light chains, each 
comprised of two compact globular subdivisions or domains (VL and CL), and two identical 
heavy chains with four domains (VH and CH1, 2, 3) (Butler et al., 2009).  Intra-chain and inter-
chain disulfide bridges hold the molecule together and provide stability (Wang et al., 2007).  
Intra-chain disulfide bridges link two amino acids within the same domain and inter-chain 
disulfide bridges link two amino acids on different heavy or light chains (Liu et al., 2008).  An 
oligosaccharide located between the heavy chains functions in modulating antibody interaction 
with complement molecules and FcRs and also reduces the susceptibility of the antibody to 
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degradation by proteases (Arnold et al., 2007; Mimura et al., 2001; Raju and Scallon, 2006; 
Wang et al., 2007).   
 
This general antibody model holds for nearly all mammalian species; camelids (camels, llamas, 
alpacas, guanacos, etc.) are one exception.  In these species, antibodies differ from the general 
model most notably by the fact that they are heavy-chain-only antibodies (HCAbs) with 
functional single-domain fragments (VHH or Nanobody®) (De los Rios et al., 2015; Harmsen 
and Haard, 2007).  In mammalian species in which the general model applies, five isotypes are 
recognized (IgG, IgM, IgA, IgD, IgE).  Isotypes are differentiated on the basis of the heavy chain 
constant regions characteristics:  1) non-cross-reacting antigenic determinants; 2) amino acid 
sequence; and 3) number and location of oligosaccharides (Kenneth, 2012; Shade and Robert, 
2013).  Antibodies can be either monomeric (IgG, IgE, IgD) or polymeric (IgM, IgA).  In IgM 
and IgA, a 'tailpiece' in the heavy chain constant region connects multiple monomers via a 
polypeptide ("J chain") produced by the B cell.  This connection results in the creation of new 
disulfide bridges that stabilize the polymer structure (Butler et al., 2017; Shade and Robert, 
2013).   
 
Antibody stability is the tendency of the molecule to maintain its structural conformation and 
functionality (Jacob et al., 2006).  This discussion will focus on IgG because it is the most 
important immunoglobulin in diagnostic medicine (Chelius et al., 2005; Vidarsson et al., 2014).  
This reflects the fact that it is the most abundant immunoglobulin in serum, e.g., IgG constitutes 
~88% of the total serum antibody in cattle and swine (Butler et al., 2017; El-Loly, 2007; Hurley 
and Theil, 2011).  However, diagnostically-useful levels of IgG are also found in nearly every 
conceivable diagnostic specimen, e.g., colostrum, milk, oral fluids, urine, feces, and meat 
exudate ("meat juice") (Butler et al., 2017; El-Loly, 2007; German et al., 1998; Mortensen et al., 
2001; Pricket et al., 2008).  IgG is present in nearly every compartment and fluid because 
neonatal Fc receptors (FcRn) widely distributed in epithelial tissues selectively bind IgG and 
actively facilitate its bidirectional transport across tissue barriers (Roopenian and Akilesh, 2007; 
Ward et al., 2015; Yoshida et al., 2004). 
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IgG trends to be more stable in vitro than other proteins because of its globular rigid structure 
and multiple cross-linked bonds (Lumry and Eyring, 1954).  However physicochemical 
processes can affect to its stability and functionality, as discussed in the following sections 
(Ishikawa et al., 2010b; Jacob et al., 2006; Lumry and Eyring, 1954).  Specific limitations in this 
discussion should be recognized:  1) the majority of the information is based on studies of human 
antibodies, 2) the mechanisms involved are not always fully understood, and 3) the high degree 
of homology in the mammalian IgG primary structure suggests a similar pattern of susceptibility 
among antibodies within the isotype, but minor variation in structure or composition likewise 
infers some variability in stability (An, 2010; Butler et al., 2017; Esteves and Binaghi, 1972; 
Ishikawa et al., 2010b; Jacob et al., 2006; Vidarsson et al., 2014).   
 
Physicochemical processes that affect IgG stability 
Protein denaturation 
At its simplest, four levels of protein structure are recognized:  primary (amino acid sequences), 
secondary (alpha helices and beta sheet formation), tertiary (three-dimensional folded structure), 
and quaternary (assemblies of more than one amino acid chain).  Denaturation of proteins is thus 
defined as changes in conformation (unfolding) that affect structure and/or functionality (Lumry 
and Eyring, 1954).  Changes in the tertiary or quaternary structures may be reversible; changes in 
the primary or secondary structures are irreversible.  Antibodies fulfill their biological activity 
only when they are correctly folded; unfolding leads to conformational instability, permanent 
denaturation, and changes in binding activity, including inter-antibody interactions (Lumry and 
Eyring, 1954; Rocco et al., 2008).   
 
Protein aggregation  
First described by Lumry and Eyring (1954), aggregation or "oligomerisation" is protein self-
association (Jacob et al., 2006; Kiese et al., 2008; Rouet et al., 2014).  Proteins may aggregate by 
physical association with one another and without any changes in primary structure (physical 
aggregation) or by formation of new covalent bond(s) (chemical aggregation).  Physical 
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aggregation occurs after the tertiary structure unfolds sufficiently so as to expose hydrophobic 
zones and change the antibody polarity, thereby triggering aggregation (Fincke et al., 2014; 
Wang, 2005).  Chemical aggregation results from the formation of disulfide bonds among 
antibodies or antibody fragments (Fincke et al., 2014).   
 
Polymerization 
Polymerization is the combination of ≥ 2 small and similar molecules (monomers) to form a new 
macromolecule (polymer) (Heck et al., 2013; Yamaguchi et al., 1998).  Antibody polymerization 
is result of the formation of new covalent bonds between two or more similar protein structures 
(protein crosslinking), with IgM and IgA being examples of naturally-occurring polymers 
(Chapuis and Koshland, 1974; Heck et al., 2013).  Polymerization can be produced by chemicals 
that generate covalent bonds between lysine amino acids in the heavy chains of the IgG structure.  
For example, glutaraldehyde, generates larger, insoluble IgG polymers under pH 7 or smaller 
soluble IgG polymers under pH 9 (Yamaguchi et al., 1998).  In contrast with other antibody 
physicochemical processes, polymerization is generally not temperature-dependent (Yamaguchi 
et al., 1998).   
 
Isomerization  
Isomerization is the transformation of one molecule into another as a result of a rearrangement in 
the atoms (Wakankar et al., 2007).  Isomerization occurs spontaneously under normal 
physiological temperatures (Geiger et al., 1987).  Aspartate, an important amino acid component 
of antibodies, is highly susceptible to isomerization when it is followed by small amino acids, 
e.g., serine, alanine, cysteine or glycine, and/or when it is in a slightly acidic environment 
(Sydow et al., 2014; Wakankar et al., 2007; Yan et al., 2016).  Antibody isomerization usually 
occurs in the Fab hypervariable region (HV) region, thereby increasing its flexibility and 
unpredictably affecting binding affinity (Yan et al., 2016).  The conditions under which aspartate 
isomerization occurs are not well understood and possibly differ among subclasses of IgG 
(Sydow et al., 2014; Yan et al., 2016).   
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Figure 2.2. Deamidation of asparagine or glutamine (amino acids involved in antigen-antibody 
interactions) may affect antigen binding. 
 
Deamidation 
Deamidation is a spontaneous reaction in which an amino acid, either asparagine or glutamine, is 
changed or removed, thereby affecting the primary structure of the protein (Chelius et al., 2005; 
Haberger et al., 2014; Jacob et al., 2006).  Deamidation had been studied, often in conjunction 
with isomerization, since the 1980’s as a means of altering protein structure and function (Geiger 
et al., 1987).  Since asparagine and glutamine are primarily located in the light chain (L) of the 
Fab and hypervariable (HV) regions, deamidation directly affects antibody biding affinity 
(Sydow et al., 2014) (Figure 2).  Deamidation of IgG can occur under temperature and/or pH 
stress (Chelius et al., 2005; Haberger et al., 2014; Sydow et al., 2014).  Susceptible regions of the 
molecule have been identified, but the mechanism(s) of deamidation are poorly understood 
(Sydow et al., 2014).   
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Figure 2.3. Methionine oxidation.  Oxidation in heavy chain region may affect FcRs-IgG 
interactions.  Oxidation in the hypervariable region may affect antigen-IgG 
interactions. 
 
Oxidation 
Oxidation is a chemical process in which a molecule loses electrons (Chumsae et al., 2007; 
Folzer et al., 2015).  In antibody molecules, oxidation modifies interactions between amino acids 
and may disrupt peptide bonds, thereby affecting the primary structure of the protein (Lam et al., 
2008; Lewis et al., 2017; Lumry and Eyring, 1954).  Methionine, an important antibody 
constituent, is highly susceptible to oxidation (Folzer et al., 2015; Lam et al., 2008).  Methionine 
is distributed throughout the IgG molecule, but oxidation of methionine in the Fc region affects 
the antibody's capacity to interact with FcRs and complement (Mo et al., 2016; Smith et al., 
1954; Yamashita et al., 1968; Yan et al., 20160) (Figure 3).  Others amino acids are likewise 
susceptible to oxidation, e.g., tryptophan, phenylalanine, tyrosine, cysteine, and histidine, but 
their interior location in the molecule restricts their exposure to oxidizers (Chumsae et al., 2007; 
Folzer et al., 2015; Jacob et al., 2006).   
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Enzymatic processes that affect IgG 
Enzymatic degradation of hemoglobin by papain and pepsin was reported in the 1930's (Anson 
and Mirsky, 1932; Anson, 1937).  Using the same approach, Porter (1950) demonstrated a 
reduction in antigen-antibody interactions after enzymatic antibody fragmentation.  Papain and 
pepsin are non-specific proteases capable of fragmenting all antibody isotypes under 
physiological conditions (pH 7, 37°C).  However, papain has higher activity on phenylalanine, 
lysine, and glycine, whereas pepsin has higher activity on phenylalanine, tryptophan, and 
tyrosine (Bennett et al., 1997).  Papain preferentially cleaves IgG at the hinge region, dividing 
the antibody into an Fc portion and linked or separated Fab portions (Bennet et al., 1997).  
Pepsin cleaves the IgG molecule below the hinge region, dividing the antibody into a linked Fab 
portion and an Fc portion, which is often further fragmented (Bennet et al., 1997; Lipman et al., 
2005) (Figure 4).   
 
Enzymatic fragmentation at the hinge region is also used by bacteria to evade the phagocytosis, 
e.g., the family of Streptococcus suis Ig-degrading enzymes (IdeS) (Pawel-Rammingen et al., 
2002; Seele et al., 2015; Spoerry et al., 2016).  Some IdeS enzymes have highly specific 
proteolytic activity, e.g., the S. suis IgdE enzyme specifically cleaves the porcine IgG hinge 
region and the S. suis IdeSsuis enzyme exclusively cleaves porcine IgM, but not IgM from other 
species (Seele et al., 2013; Spoerry et al., 2016).  IgG Fab and Fc fragments retain specific 
binding functions, but the separate components are unable to trigger a complete immunological 
response (agglutination, precipitation, opsonization, etc.) and do not perform adequately in 
diagnostic assays. 
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Figure 2.4. Antibody fragmentation by enzymatic fragmentation.  Protease papain (A) cleaves 
the hinge region, dividing the IgG molecule into an Fc portion and linked or 
separated Fab portions.  Protease pepsin (B) cleaves the IgG molecule below the 
hinge region, dividing the antibody into a linked Fab portion and an Fc portion, 
which is often further fragmented 
 
B 
A 
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Considerations for diagnostic specimens 
The intent of this section is to discuss the physicochemical and enzymatic processes described 
above in the context of specimen handling and storage in the laboratory (Jacob et al., 2006; 
Wang et al., 2007).   
 
The temperature-by-time-dependent denaturation of IgG is the single most important 
consideration in the handling and storage of diagnostic samples (Fincke et al., 2014; Jacob et al., 
2006; Underwood et al., 1985; Wang et al., 2007).  That said, a "unified formula" describing this 
relationship has not been described, perhaps because the reports in the peer-reviewed literature 
differ considerably in: 1) antibody evaluated, 2) specimen or matrix, 3) temperature and time 
evaluated, 4) assay(s) used to measure the effect, and 5) strength of the experimental design.   
 
Regardless, it is recognized that sufficient temperature over time causes unfolding of the 
secondary and tertiary structures of IgG, i.e., non-reversible and reversible changes, respectively 
(Vermeer and Norde, 2000).  Vermeer and Norde (2000) found that the combination of 20 
minutes at 70°C was sufficient to completely denature IgG in phosphate buffered solution (PBS, 
pH 8.1).  Heat-induced changes in protein structure can lead to antibody aggregation.  Thus, 
Hawe el al. (2009) reported that 12% of IgG aggregated in PBS (pH 7.2) after 15 minutes at 
77°C.  Fincke et al. (2014) found that 29.5% of IgG aggregated in an IgG formulation (pH 7.5) 
after 72 hours at 60°C and 10% after 5 weeks at 40°C.  These conditions reduced the 
concentration of monomeric IgG from 97.5% to 64.5% and from 100% to 90.3% respectively (t-
test, p < 0.01).  In addition to aggregation, thermal stress can also facilitate other 
physicochemical processes that affect IgG functionality (Jacob et al., 2006).  Xanthe et al. (1997) 
reported the oxidation of IgG in a buffered solution containing sodium acetate, NaCl, and 
polysorbate (pH 5.0).  Two weeks of exposure at 5°C resulted in specific oxidation of 10% of the 
methionine in the Fc region, 17% at 30°C, and 52% at 40°C.  However, even in the worst case, 
this resulted in less than a 10% reduction in antibody binding activity (Xanthe et al., 1997).  
Deamidation of IgG can also be triggered by prolonged exposure (2 to 4 weeks) at 40°C (pH 
15 
 
 
 
 
6.0).  This can result in specific deamidation in the HV regions and a decrease of 10% of IgG 
binding activity (Haberger et al., 2014; Sydow et al., 2014).   
 
In contrast with the effect of thermal stress on antibody, the freeze-thaw cycle specimens 
commonly undergo in the laboratory setting has little effect on IgG (Hawe et al., 2009).  Hawe et 
al. (2009) found that five freeze-thaw cycles (-80°C, 20-25°C) reduced the concentration of IgG 
in PBS (pH 7.2) by 0.15% (Hawe et al., 2009).  However, one cycle consisting of snap freezing 
in liquid nitrogen followed by thawing at room temperature aggregated of 32.7% of bovine IgG 
in PBS (pH 7.2) (Sarciaux et al., 1999).   
 
In addition to temperature and time effects, an additional consideration for the stability of IgG in 
diagnostic specimens is the presence of bacterial contaminants.  For example, ELISA-detectable 
IgG declined after 2 days in swine oral fluids held at 30°C, but was extended to 12 days in 
samples held at 10°C, 14 days at 4°C, and months or more in samples stored -20°C/-80°C 
(Henao-Diaz et al., 2017; Pricket et al., 2010).  Lower temperatures were associated both with 
increased IgG stability and with less bacterial proliferation in the specimen.  A similar effect was 
observed in samples treated with antimicrobial and/or antiproteolytic agents.  Thus, ELISA-
detectable IgG was stable for up to one month at room temperature in human saliva collected 
with a commercial device containing antimicrobial and antiproteolytic compounds (Thwe et al., 
1999).  Likewise, Pricket (2010) observed similar trends in swine oral fluids treated with a 
bacteriostat (chlorhexidine digluconate, 0.01% by volume).  
 
Conclusions 
Structural differences in mammalian IgG subclasses can manifest themselves as variation in 
susceptibility to physicochemical and external factors that affect antibody stability and 
diagnostic functionality.  Mammalian species share a common core structure in their IgG, thus 
general conclusions are broadly applicable to diagnostic laboratory testing.  The stability of IgG 
in the diagnostic setting reflects the intrinsic physicochemical processes that affect IgG structural 
integrity and the characteristics of the specimen.   
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The first principle in conserving IgG diagnostic functionality is avoidance of thermal stress.  In 
general, IgG is stable for less than 20 minutes at 70°C, 1 - 2 hours at 60°C, < 2 days at 20°C - 
40°C, 1 - 2 weeks at 4°C, and indefinitely -20°C, -80°C.  Snap freezing should be avoided 
because abrupt changes in temperature affect antibody integrity and increases aggregation.  IgG 
is highly resistant to repeated "standard" freeze-thaw cycles, but care should nonetheless be 
taken.  For example, splitting a sample into multiple aliquots is recommended as a means to 
avoid multiple freeze-thaw cycles.  Human IgG is stable at pH 5.0 - 5.5, but pH stability varies 
among antibody subclasses.  For this reason, and particularly when the matrix has been modified 
by the addition of a buffer, good quality control would include measuring and recording the pH 
on the sample label.  Additional factors, e.g., exposure to light, mechanical stress (shaking, 
stirring), or hydrogen ion concentration (pH) can be hazardous for antibody in diagnostic 
specimens.  However, these factors typically represent minor threats to IgG stability under 
typical laboratory scenarios (Kiese et al., 2008; Lumry and Eyring, 1954; Prickett et al., 2010). 
 
The majority of peer-reviewed research has focused on the stability of IgG in serum samples.  
However, new specimen types are increasingly used in the veterinary diagnostic setting, e.g., 
mammary secretions, fecal specimens, and oral fluids.  These specimens may require additional 
manipulation, e.g., Pricket et al. (2010), showed that the addition of a bacteriostatic improved the 
stability of antibody in swine oral fluid over time.  Identifying and understanding the processes 
that affect IgG functionality and stability in these alternative diagnostic specimens will be an 
important process in assuring diagnostic accuracy.  
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Abstract 
Routine collection and testing of oral fluid (OF) samples facilitates PRRSV surveillance in 
commercial swine herds in a cost-effective, “welfare-friendly” fashion.  However, OF often 
contain feed, feces, and environmental contaminants that may affect liquid handling and test 
performance in the laboratory.  Traditional sample processing methods, e.g., filtration or 
centrifugation, are not compatible with high-throughput laboratories because of the burden of 
additional processing costs and time.  OF "clarification" using chemical coagulants is an 
alternative approach not widely explored.  Therefore, the objective of this study was to evaluate 
the effect of chitosan-based clarification treatment on a commercial PRRSV OF ELISA and the 
temporal stability of ELISA-detectable antibody in samples held at 4°C.   
Serum and OF samples of known status were generated by vaccinating pigs (n = 17) with a 
PRRSV MLV vaccine.  Individual pig OF samples were collected from day post vaccination -7 
to 42 and subdivided into 4 aliquots.  Each aliquot was clarified using one treatment (A, B, C) 
with the 4th aliquot serving as untreated control.  All samples were tested by PRRSV OF ELISA 
immediately after treatment (day post-treatment DPT 0) and then were held at 4°C to be re-tested 
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on DPTs 2, 4, 6, and 14.  Both immediate and temporal treatment effects were evaluated for their 
quantitative and qualitative effects on PRRS OF ELISA performance.     
A repeated measures multiple comparison analysis with Tukey adjustment found no significant 
difference in ELISA S/P responses among treatments by DPT.  Among all DPTs, no difference 
was detected in the proportion of positive PRRSV antibody samples among treatments 
(Cochran's Q, p > 0.05).   
Treatment of swine oral fluids using chitosan-based formulations did not affect the performance 
of a commercial PRRSV OF ELISA either immediately after treatment or up to 14 days after 
treatment.  Chitosan (or other coagulants) could improve the OF characteristics and could be 
adapted for use in the field or in high-throughput laboratories.   
 
Keywords: PRRSV, oral fluid, ELISA, chitosan, clarification, antibody stability.    
 
 
Introduction  
Since its recognition in 1991 (Terpstra et al., 1991), porcine reproductive and respiratory 
syndrome virus (PRRSV) has continually challenged pork producers and swine veterinarians.  
Holtkamp et al. (2013) estimated the cost of PRRSV to U.S. producers at more than $660 million 
per year.  De Pax et al. (2015) using prevalence estimates from 11 countries, extrapolated the 
costs of PRRSV to European producers at €1.5 billion per year.  Likewise, in Asia, PRRSV 
imposes heavy economic consequences due to clinical and subclinical infections plus the cost of 
prevention and control measures (McOrist et al., 2011; Zhang and Kono, 2012). 
 
The only two options for the control of PRRSV are (1) elimination of the virus from the herd or 
(2) reduction of clinical signs through enhancement and stabilization of herd immunity via 
vaccination or intentional exposure (Linhares et al., 2014).  In both cases, implementation of 
biosecurity protocols sufficient to stop the introduction of extraneous viruses is mandatory.  
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Regardless of the control plan, routine sampling and testing is necessary to verify that the chosen 
strategy is functioning - because clinical signs are not a reliable or timely indicator of PRRSV 
infection (Duinhof et al., 2011; Frössling et al., 2009).  Depending on the circumstances, the 
survey objective will be either surveillance (detection of PRRSV) or monitoring (tracking the 
circulation of the virus in an endemically infected population) (Paskin, 1999). 
 
Routine surveillance or monitoring using serum samples is not practical because of the time and 
cost associated with collecting a statistically sufficient number of samples on a continuous basis.  
In contrast, oral fluid-based testing offers the possibility of collecting population infectious 
disease data easily, quickly, inexpensively, and in a “welfare-friendly” fashion (Ramirez et al., 
2012; White et al., 2014).  Both PRRSV nucleic acid- and antibody-based assays have been 
adapted to oral fluid specimens (Kittawornrat et al., 2012; Prickett and Zimmerman, 2010) and 
studies have shown field studies based on oral fluid specimens equal or exceed PRRSV detection 
based on serum (Biernacka et al., 2016; Ramirez et al., 2012). 
 
While offering practical advantages for routine PRRSV detection, oral fluid samples commonly 
contain insoluble particles from the environment, e.g., feed, feces, and inorganic material.  These 
contaminants have not been shown to directly affect test performance, but in the laboratory, these 
contaminants may affect liquid handling characteristics, e.g., the precision of pipetting.  The only 
options for removing particulates from oral fluids are prolonged, high-speed centrifugation or 
filtration, but neither is practical in a high throughput laboratory.  A third option is 
"clarification", i.e., the removal of particles suspended in a solution, using chemical coagulants.  
Coagulants function by destabilizing the charge on the surface of the particles, thereby allowing 
them to flocculate (aggregate) into larger elements that can be more easily removed.   
 
Among the many options, chitosan (deacetylate chitin) is an abundant, biodegradable, 
biocompatible, and non-toxic coagulant that has been used in a variety of biological applications 
(Hirano, 1996), e.g., production of foods (Del Nobile et al., 2009) and beverages (Domingues, 
2012; Gassara et al., 2015; Mierczynska-Vasilev, 2015), improved drug delivery systems (Park, 
2010), adjuvantation of vaccines (Li et al., 2015; Wen, 2011), and clarification of cell culture 
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media (Riske et al., 2007).  Previously, Poonsuk et al. (2017) showed that chitosan could be used 
to clarify swine oral fluid specimens and that treatment did not affect porcine epidemic diarrhea 
virus IgA or IgG ELISA test results.  Therefore, the aim of the current study was to evaluate the 
effect of chitosan-based clarification of oral fluids on the performance of a commercial PRRSV 
antibody IgG ELISA (IDEXX PRRS OF Ab Test™, IDEXX laboratories, Westbrook, ME, 
USA).   
 
Methods  
Experimental design 
This study was conducted with the approval of the Iowa State University Office for Responsible 
Research.  In brief, oral fluid and serum samples of known PRRSV antibody status were 
generated by vaccinating (Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica, Duluth, 
GA, USA) pigs under experimental conditions and then collecting samples over a period of 50 
days.  Following each collection, oral fluid samples were subdivided into 4 aliquots, each of 
which was subjected to one of four treatments (Control, A, B, C) and then tested for PRRSV 
antibody (day post treatment, DPT 0).  Thereafter, the treated oral fluid specimens were stored at 
4°C and re-tested on DPT 2, 4, 6, and 14.  At the end of the study, the oral fluid PRRS ELISA 
sample-to-positive (S/P) results were analyzed for the effect of treatment, storage time, and 
storage time-by-treatment interactions.   
 
Animal care 
PRRSV-negative pigs (n = 17) were acquired from a commercial swine farm at 14 weeks of age 
(~40 to 50 kg) and housed in biosafety level 2 (BSL-2) research facilities accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).  
Negative PRRSV status was verified by ELISA testing of serum samples collected 14 and 7 
days prior to the arrival of the animals.  In addition, the final set of serum samples was pooled 
(≤ 5 samples per pool) and tested by PRRSV qRT-PCR to verify the absence of acute PRRSV 
infection.  
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Upon arrival (13 days prior to vaccination), pigs were randomly assigned ID numbers by blindly 
pulling ear tags from a bag and then assigned to individual pens consecutively by ear tag 
number.  Pens (1.5 m × 1.8 m) were constructed of solid partitions and gates.  All pens had 
gates on at least two sides to allow interaction between animals in neighboring pens.  Each pen 
was equipped with a nipple drinker and a bracket to hold a rope during oral fluid collection.  
Pigs were fed a commercial swine diet (Heartland CO-OP, Prairie city, IA, USA) twice per day.  
Animals were closely observed throughout the study by researchers, animal caretakers, and 
institutional veterinary staff.  Five animals were observed through day post vaccination (DPV) 
28 and then removed due to facility space limitations; the remainder (n = 12) were observed 
through DPV 42.    
 
Vaccination 
All animals were vaccinated intramuscularly on DPV 0 with 2 ml of a PRRSV modified-live 
vaccine (Ingelvac® PRRS MLV) using a single-use syringe and needle (PrecisionGlide™, 
Becton Dickson, Franklin Lakes, NJ, USA),   
 
Serum and oral fluid sample collection    
Pigs were allowed to acclimate for 5 days before initiation of sampling.  Oral fluid and serum 
samples were collected between DPV -7 to DPV 42.  The number of oral fluid and serum samples 
collected and evaluated in this experiment is given in Table 2 by DPV.  
 
Serum samples (n = 187) were collected using a single-use vacutainer system (Corvac™ Integrated 
Serum Separator Tube, 12.5 ml, Covidien, Minneapolis, MN, USA).  No pig was bled on 
consecutive days; rather, subsets of pigs were rotated through the sampling schedule so as to obtain 
serum samples for DPV 3, 6, 7, 8, 9, and 10 (Table 2).  Blood samples were centrifuged (1,500 × 
g for 15 min) and then serum was aliquoted into 2 ml tubes (Cryos™, Greiner Bio-One, Monroe, 
NC, USA) and stored at -80ºC.  
 
30 
 
 
 
 
Oral fluid samples (n = 221) were collected with three-strand twisted 100% cotton rope (Web 
Rigging Supply, Lake Barrington, IL, USA) hung from a metal bracket fixed to one side of the 
pen.  Brackets were placed such that samples could be collected without entering the pen.  During 
the acclimation period, pigs were given access to the rope for two 30 minute periods daily.  The 
sampling procedure has been described in detail (González et al., 2017; White et al., 2014).  In 
brief, pigs were allowed to interact with the rope for 30 min, then the wet the end of the rope was 
cut, inserted into a plastic bag (Seal-Top Bag, Elkay Plastics, Commerce, CA, USA), and passed 
through a towel wringer (WC38K, Dyna-Jet products, Overland park, KS, USA).  The oral fluid 
that accumulated in the bag was then decanted into a 50 ml polypropylene centrifuge tube 
(Falcon™, Fisher Scientific, Pittsburgh, PA, USA).  To maximize the volume collected, oral fluid 
samples were collected twice daily (8:00 am and 4:00 pm).  Oral fluid samples collected in the 
morning were placed on ice, pooled with the afternoon sample, and then the composite sample 
aliquoted into 5ml tubes (Fisher Scientific, Pittsburgh, USA) and stored at -80ºC. 
 
PRRSV serum qRT-PCR 
Viral RNA was extracted from 140 µl of serum and eluted to 90 µl of elution buffer using 
QIAmp® viral RNA mini kit (QIAGEN® GmbH, Hilden, Germany) following the instructions 
provided by the manufacturer.  The eluted RNA, primers, and probe were mixed with 
commercial reagents (EZ-PRRSV™ MPX 4.0 real time RT-PCR, Tetracore®, Rockville, MD, 
USA).  NA PRRSV, EU PRRSV, and internal controls were included in every reaction.  The 
qRT-PCR reactions were done using the T-COR 8™ thermocycler (Tetracore®):  48°C for 15 
min, 95°C for 2 min, 95ºC for 5 s (45 cycles), and 60ºC for 40 s.  The results were analyzed 
using an automatic baseline selected by the T-COR 8™ software.  Quantification cycle (Cq) 
values ≤ 40 were considered positive for PRRSV.   
 
PRRSV serum ELISA  
Serum samples were tested for PRRSV antibody using a commercial ELISA (IDEXX PRRS X3 
Ab Test™, IDEXX Laboratories Inc.) performed as instructed by the manufacturer.  In brief, 5 
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µl of serum was diluted 1:40 with sample diluent in 96-well polystyrene plates (Nunc™ A/S, 
Roskilde, Denmark) and then 100 µl of the mixture was transferred to an ELISA plate followed 
by 30 min incubation (19 - 22°C).  Plates were then washed 5 times with 300 µl of 1X wash 
solution, 100 µl of conjugate was added to each well, and the plates were incubated for another 
30 min.  The washing cycle was repeated, then 100 µl of tetramethylbenzidine-hydrogen 
peroxide substrate (TMB) was added to each well and the plates incubated for 15 min to 
visualize the reaction.  Thereafter, 100 µl of stop solution was added to each well and the plate 
was read (650 nm) using an ELISA plate reader (EMax® Plus microplate reader, Molecular 
devices, Sunnyvale, CA, USA) operated with the SoftMax® Pro 7 software (Molecular devices).  
The antibody responses in serum samples were calculated as sample-to-positive (S/P) ratios 
using equation 1.  Serum samples with S/P ratios ≥ 0.40 were considered PRRSV serum 
antibody positive. 
 
Equation 1: 
S/P ratio =  
(sample OD – negative control mean OD) 
(positive control mean OD – negative control mean OD) 
 
 
PRRSV oral fluid ELISA  
Oral fluid samples were tested for PRRSV antibody using a commercial ELISA (IDEXX PRRS 
OF Ab Test™, IDEXX Laboratories Inc.) performed as instructed by the manufacturer.  In brief, 
100 µl of oral fluid was diluted 1:1 with sample diluent in 96-well polystyrene plates (Nunc™) 
and then 100 µl of mixture was transferred to the ELISA plate.  After 2 h incubation (19 - 22°C), 
plates were washed 5 times using 350 µl of 1X wash solution, then 100 µl of conjugate was 
added to each well and the plates incubated for 30 min.  The wash cycle was repeated and 100 µl 
of tetramethylbenzidine-hydrogen peroxide substrate (TMB) were added to each well and the 
plates incubated for 15 min to visualize the reaction.  Thereafter, 100 µl of stop solution was 
added to stop the reaction and the plates read (450 nm) using an ELISA plate reader (Biotek® 
Instruments Inc., Winooski, VT, USA) operated with the IDEXX xChek® software (IDEXX 
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Laboratories Inc).  Antibody responses in oral fluid samples were calculated as sample-to-
positive (S/P) ratios using Equation 1.  Oral fluid samples with S/P ratios ≥ 0.40 were considered 
positive. 
 
Oral fluid clarification treatments 
Three chemical clarification treatments (A, B, C) were prepared, as described elsewhere 
(Poonsuk et al., 2017).  The components and quantities used to prepare 100 ml of each treatment 
are listed in Table 1.  Following preparation, 1 ml was pipetted into 5 ml round-bottom 
polystyrene tubes (Falcon™), held at -80ºC for 24 h, and then lyophilized (FreeZoneTM, 
Labconco®, Kansas City, MO, USA) for 15 h.  After lyophilization, tubes were closed with 
polyethylene caps (Falcon™), vacuum sealed in plastic bags, and stored at room temperature (19 
- 22°C) until use.   
 
Immediate effect of treatment     On day post treatment (DPT) 0, oral fluid samples (n = 221; > 4 
ml) were thawed at room temperature (19 - 22°C) and vortexed for 5 sec.  Oral fluid (1 ml) was 
then added to each of the three clarification treatments tubes (A, B, and C) and to an empty 5 ml 
round-bottom polystyrene tube (negative control, NC).  Samples were vortexed to resuspend the 
chemical components (5 sec), centrifuged at 1200×g for 3 min at 4ºC, randomly ordered 
(www.random.org), and tested for PRRSV antibody (IDEXX Laboratories Inc).   
 
Temporal effect of treatment     After testing on DPT 0, all samples (n = 884; A, B, C, NC) were 
held at 4ºC in an environmental chamber (Caron®, Marietta, OH, USA) and re-tested on DPT 2, 
4, and 6.  A subset (n = 352), i.e., oral fluid samples collected on DPV -7, 6, 7, 8, 9, 10, 14 and 
42, was held and tested on DPT 14.  Oral fluid samples were neither vortexed nor centrifuged 
prior to testing on DPT 2, 4, 6, and 14. 
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Data analysis 
The effect of clarification treatments on the PRRSV oral fluid ELISA S/P ratios and antibody 
status (positive or negative) was analyzed using statistical software (MedCalc® 17.6, MedCalc 
Software bvba, Ostend, Belgium; SAS® 9.4, SAS® Institute Inc., Cary NC, USA).  Initially, the 
effect of oral fluid treatment was analyzed separately for oral fluid samples collected prior to the 
expected appearance of detectable antibody (≤ DPV 7, "early samples") and oral fluids collected 
after the expected appearance of antibody (≥ DPV 14, "late samples").  The assumption of 
normality for the "early" and "late" datasets was rejected (Shapiro-Wilk test) and transformation 
of the data did not achieve normality.  Therefore, a nonparametric approach (Kruskal-Wallis test) 
was used to evaluate the effect of treatment on S/P values for each dataset within each DPT (0, 2, 
4, 6, and 14).  Thereafter, the complete dataset was analyzed for the effect of treatment (NC, A, 
B, C) and storage time (DPT 0, 2, 4, 6, 14) on S/P ratios using a repeated measure multiple 
comparison test with Tukey adjustment (Proc GLIMMIX).  Cochran's Q test was used to 
evaluate differences in the proportion of antibody positive results (S/P ≥ 0.40) among treatments 
within DPTs and within treatments among DPTs.   
 
Results  
Pigs were determined to be naïve for PRRSV infection at the time of arrival on the basis of 
negative ELISA and qRT-PCR results on serum samples collected prior to arrival.  In addition, 
all serum and oral fluid samples collected prior to DPV 7 were ELISA negative.  No clinical 
signs or adverse health events were observed over the course of the observation period.   
 
A total of 187 serum samples were collected over the course of the study and tested by PRRS 
ELISA.  The number of samples collected vis-à-vis the number of ELISA positives (S/P ≥ 0.4) is 
given in Table 2 by DPV.  Serum antibody ontogeny (ELISA S/P response) is shown in Figure 1. 
 
A total of 221 oral fluid samples of volume sufficient to make 4 aliquots (each of 1 ml) were 
collected over the course of the experiment.  The lyophilized treatments (A, B, C) were readily 
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rehydrated by adding 1 ml of oral fluid and vortexing briefly.  Untreated samples were readily 
differentiated from treated samples by the light blue color conferred by the xylene cyanol present 
in formulations A, B, and C.   
 
PRRSV OF ELISA test results for all oral fluid samples on DPT 0 are given in Figure 1 and 
Table 2.  Among DPTs 0, 2, 4, 6, and 14, no difference was detected in the proportion of positive 
PRRSV antibody samples among treatments (Cochran's Q test, p > 0.05).   
 
The effect of oral fluid treatment on ELISA S/P responses was analyzed separately for oral fluid 
samples collected prior to the expected appearance of detectable antibody (≤ DPV 7, "early 
samples") and oral fluids collected after the expected appearance of antibody (≥ DPV 14, "late 
samples") for DPTs 0, 2, 4, 6, and 14 (Table 3).  At DPT 0, 2, 4, and 6 a statistically significant 
difference in the "early samples" S/P response was detected between treatments A or C versus 
NC or B (Kruskal-Wallis test, p < 0.0001).  For “late samples”, no differences were detected 
between treatments (NC, A, B, C).   
 
An analysis of the complete dataset using a repeated measures multiple comparison test with 
Tukey adjustment found no significant difference in ELISA response between treatments (NC, 
A, B, C) at each storage time (DPT 0, 2, 4, 6, 14).  Likewise, no interaction was detected 
between treatment and storage time on ELISA S/P ratios.  Analysis within treatments showed 
differences (p < 0.05) in S/P responses among DPTs, but the direction of change was 
inconsistent and not compatible with antibody degradation or inactivation 
 
Discussion  
The diagnostic use of swine oral fluid specimens began with the isolation of PRRSV from buccal 
swabs (Wills et al., 1997).  Thereafter, Prickett et al. (2008a) showed that ELISA-detectable 
PRRSV antibodies appeared concurrently in serum and oral fluid matrices and explored the use 
of pen-based oral fluid samples under experimental conditions.  Pepin et al. (2015) reported the 
appearance of ELISA-detectable antibody in oral fluids collected in boars 7 days after 
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administration of a modified-live vaccine.  In the field, Kuiek et al. (2015) found a strong 
temporal association in the ontogeny of oral fluid and serum antibody, while Kittawornrat et al. 
(2012, 2013) showed the concurrent appearance of serum and oral fluid PRRSV antibody 
isotypes (IgM, IgG, IgA) under both experimental and field conditions.  Overall, the antibody 
results of this study were compatible with earlier reports.  In particular, the design of the study, 
i.e., 17 individually-penned pigs sampled over a period of 50 days, allowed for a precise estimate 
of the earliest appearance of ELISA-detectable antibody because a three-day bleeding rotation 
schedule provided paired serum samples and oral fluid specimens every day during the expected 
period of seroconversion (DPV 3 to 11).   
 
The current research differed from previous studies with its focus on the oral fluid specimen 
itself.  As reviewed by Faust and Osman (1998), "clarification" of liquids, i.e., the removal of 
suspended particulates, has a long historical thread.  The ancient Minoans (Angelakis and Zheng, 
2015), Egyptians, and early Romans clarified drinking water by sedimentation and/or treatment 
with crushed almonds or clay containing mineral salts.  By 1757, aluminum sulfate (alum) was 
known to remove particulates from water and, in 1881, this approach was used to treat the 
municipal water supply of the town of Balton in North West England.  The coagulant properties 
of ferrous compounds were also recognized during this period and, in 1884, a perchloride of iron 
water coagulation system was implemented by the New Orleans Water Company.  Prescient of 
the future scientific foundation of water treatment, the first published scientific study on 
chemical clarification (1885) reported that the administration of alum at a rate of ~34 ppm was 
optimum for the treatment of drinking water (Faust and Osman, 1998).   
 
Drinking water was not the only liquid in need of clarification.  As society grappled with the 
problem of sanitation in the later part of the 19th century, specific inorganic chemicals, including 
alum, were shown to clarify sewage and facilitate the treatment process (Melosi, 2008).  At the 
opposite end of the spectrum, clarification ("fining") of beer and wine was done by brew masters 
and vintners to reduce turbidity.  As reviewed by Baldwin (1824) and Stuntz (1886), fining can 
be achieved with inorganic coagulants (bentonite, powdered marble, gypsum), organic 
coagulants (Isinglass, albumen, gelatin, caseins), or a combination of inorganic and organic 
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coagulants, e.g., silica with gelatin, with isinglass, or chitosan (Mierczynska-Vasilev and Smith, 
2015).   
 
Chitosan is a cationic polymer derived by high alkaline partial deacetylation from chitin, the 
biopolysaccharide structural component in the exoskeletons of arthropods (Rinaudo, 2006).  
Chitosan's chemical properties vary depending on the degree of deacetylation, polymer length, 
and product purity but it is generically considered nontoxic, biocompatible, biodegradable, and 
amenable to a wide variety of clarification applications (Alves and Mano, 2008; Rinaudo, 2006).  
For example, chitosan was used at a concentration of 3000 ppm to treat textile wastewater (Mohd 
et al., 2009), 300 ppm to clarify fruit juice (Domingues et al., 2012), 200 ppm to clarify cell 
culture mediums for antibody recovery (Riske et al., 2007), 5 ppm to clarify beer (Gassara et al., 
2015), and as low as 0.6 ppm when combined with alum for water treatment (Zeng, et al 2008).  
The objective of this study was to evaluate the effect of chitosan-based clarification of oral fluids 
on the performance of a commercial PRRSV ELISA, i.e., would chitosan reduce antibody levels 
through coagulation and/or precipitation, or interfere with the antibody-binding functions 
required for detection by ELISA?   
 
As described in Table 1, a blue dye (xylene cyanol) was added to all formulations (A, B, C) to 
allow for convenient visual differentiation of treated vs. untreated samples.  BSA (0.5%) was 
included in all treatments (NC, A, B, C) to block non-specific binding (Pruslin et al., 1991; 
Steinitz, 2000).  Chitosan was used at 100 ppm (0.01%) in formulations A and B, with treatments 
NC and C used for comparisons.  Tween® 20 (1.0 %) was added to formulations A and C to 
further reduce non-specific binding, with treatments NC and B used for comparisons.   
 
The overall conclusion that may be drawn from an analysis of the complete dataset is that neither 
treatment nor time significantly affected the ELISA quantitative (S/P) or qualitative 
(positive/negative) responses.  As shown in Table 3, statistically significant differences in mean 
S/Ps were observed among treatments in "early samples" (samples collected ≤ 7 DPV), but these 
small differences in S/P values had no diagnostic impact (Table 2) and no such effect was 
observed among treatments in "late samples" (samples collected ≥ 14 DPV).  Further, the 
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analysis of the residual effects of treatment, i.e., samples held at 4°C and tested at DPT 2, 4, 6, 
and 14 found no significant change in ELISA S/P values by treatment or time.  Although there 
are no prior reports of testing after storage at 4ºC after 14 days, the results were compatible with 
previous reports examining antibody stability in oral fluids (Morris et al., 2002; Prickett et al., 
2010; Poonsuk et al., 2017).   
 
This research represents initial attempts at improving the characteristics of oral fluid specimens.  
Providing a cleaner oral fluid sample may lead to the wider acceptance by users and improve the 
sample-handling characteristics in high-throughput laboratories.  Within the constraints of this 
study, formulation B would be the preferred method for clarification of swine oral fluids for 
ELISA because it required the fewest components.  As noted in Table 1, the cost of formula B 
components sufficient for treating one oral fluid sample (1 ml) was €0.026 or USD $0.032.  
Continuing this line of research, future efforts should include the evaluation of other coagulants 
and/or combinations of coagulants, e.g., chitosan in combination with others.  Likewise, it will 
be necessary to evaluate the compatibility of oral fluid clarification to other pathogens, antibody 
assays, and nucleic acid detection technologies.   
 
Conclusions 
Clarification of swine oral fluids using chitosan-based formulations was effective, inexpensive, 
and did not affect the performance of a commercial PRRSV oral fluid antibody ELISA (IDEXX 
PRRS OF Ab Test™) either immediately after treatment or up to 14 days after treatment.  The 
use of coagulants to clarify oral fluids could improve and standardize oral fluid sample-handling 
characteristics.  This line of research holds the potential to move oral fluid-based surveillance to 
the next level by providing a sample well-suited to testing in high-throughput laboratories.   
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Table  3.1. Treatments evaluated for their effect on swine oral fluid PRRSV antibody detection 
Component 
Treatment formulations  
Control A B C 
1X Phosphate buffer saline - 97.9 ml 98.9 ml 98.9 ml 
Bovine serum albumin1 -  0.5 g 0.5 g 0.5 g 
Stock solution 0.1% xylene cyanol2 - 100.0 µl 100.0 µl 100.0 µl 
Stock solution 1.0% chitosan3 - 1.0 ml 1.0 ml - 
Tween® 204 - 1.0 ml - 1.0 ml 
Total components cost per sample € 0.0 € 0.027 € 0.026 € 0.027 
 $ 0.0 $ 0.033 $ 0.032 $ 0.033 
1 BSA (001-000-162, Jackson Immunoresearch, West grove, PA, USA) 
2 Xylene cyanol FF (X4126, Sigma-Aldrich, St. Louis, MO, USA) 
3 Chitosan oligosaccharide lactate (523682, Sigma-Aldrich) 
4 Polyethylene glycol sorbitan monolaurate (P1379, Sigma-Aldrich) 
 
 
Table  3.2. Number of samples by day post-vaccination and qualitative PRRSV ELISA results 
Specimen  
Day post vaccination1 
-7 -5 -3 0 3 6 7 8 9 10 14 21 28 35 42 
 Serum (no. samples) 17 - - 17 4 9 4 9 4 9 17 17 17 12 12 
   PRRSV ELISA2 (no. positive) 0 - - 0 0 0 1 0 2 5 17 17 17 12 12 
 Oral fluid (no. samples) 16 16 17 15 15 13 16 16 15 15 16 15 12 12 12 
   PRRSV ELISA3 (no. positive)4 0 0 0 0 0 0 0 3 8 14 16 15 12 12 12 
1 Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica.   
2 IDEXX PRRS X3 Ab Test, IDEXX laboratories Inc. 
3 IDEXX PRRS OF Ab Test, IDEXX laboratories Inc. 
4 Qualitative results on DPT 0 were identical among all treatments (NC, A, B, C) with the 
exception that one DPV 8 oral fluid sample (reported as positive above) was negative for 
treatments B and C.  
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Table 3.3. Quantitative effect of treatment on PRRSV oral fluid ELISA1 sample-to-positive (S/P) ratios by day post-treatment 
(DPT) 
  DPT n Negative Control                  
S/P mean (95% CI) 
Treatment A          
S/P mean (95% CI) 
Treatment B          
S/P mean (95% CI) 
Treatment C          
S/P mean (95% CI) 
"Early" samples, i.e., 0 108  0.06a (0.05, 0.08)  0.02b   (0.01, 0.04)  0.05a (0.04, 0.07)  0.03b (0.01, 0.05) 
samples collected ≤ 7 2 108  0.05a   (0.03, 0.06)  0.00b (-0.01, 0.01)  0.04a (0.02, 0.05)  0.00b (-0.01, 0.01) 
days post vaccination2 4 108  0.06a   (0.05, 0.08)  0.01b (-0.01, 0.02)  0.09a (-0.01, 0.18)  0.01b (-0.01, 0.02) 
 6 108  0.04a   (0.03, 0.06)  0.00b (-0.02, 0.01)  0.02a (0.01, 0.04)  0.00b (-0.02, 0.02) 
 14   32  0.04  (0.02, 0.06)  0.04 (0.01, 0.08)  0.02 (-0.01, 0.04)  0.03 (0.00, 0.06) 
"Late" samples, i.e., 0 67  7.21 (6.57, 7.86)  7.23  (6.58, 7.87)  7.16  (6.52, 7.79)  7.22  (6.57, 7.87) 
samples collected ≥ 14 2 67  7.58  (6.93, 8.24)  7.59  (6.94, 8.24)  7.70  (7.03, 8.37)  7.61  (6.93, 8.29) 
days post vaccination2 4 67  7.93  (7.17, 8.70)  7.91  (7.15, 8.67)  8.07  (7.32, 8.82)  8.08  (7.31, 8.85) 
 6 67  7.54  (6.81, 8.27)  7.66  (6.93, 8.39)  7.74  (7.02, 8.46)  7.64  (6.91, 8.38) 
 14 20  6.74  (5.30, 8.18)  7.16  (5.81, 8.51)  7.55  (6.21, 8.89)  7.07  (5.76, 8.38) 
1 IDEXX PRRS OF Ab Test, IDEXX laboratories. 
2 Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica. 
 a,b Treatment effect by DPT 0, 2, 4, 6, 14 was analyzed separately for oral fluid samples collected prior and after to the 
expected appearance of detectable antibody (Kruskal-Wallis test).  Within DPT, differences (p < 0.05) between treatments 
are indicated by superscripted letters.  Subsequent analysis of the complete dataset detected no significant interaction 
between storage time (DPT) and treatment (repeated measure multiple comparison test with Tukey adjustment). 
4
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Figure 3.1. PRRS OF ELISA S/P results (mean) from serum1 and oral fluid2 samples by day post     
vaccination (DPV). Oral fluid samples were tested immediately following treatment            
(see Table 1).  1 IDEXX PRRS X3 Ab Test.  2 IDEXX PRRS OF Ab Test (IDEXX 
Laboratories Inc., Westbrook, ME, USA). 
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GENERAL DISCUSSION 
The use of antibody-based diagnostics methods started in the 1890's with the introduction of 
agglutination and/or precipitation assays for a variety of bacterial veterinary and/or zoonotic 
pathogens (Schoening and Creech, 1935; Merchant and Packer, 1956).  From that starting point, 
it took nearly a century to elucidate the molecular structure, biological properties, and 
extravascular distribution of antibodies.  That is, to open the door to the development of the 
antibody-based diagnostic technology (Berson et al., 1956; Coons, 1942; Yalow and Berson, 
1960; Wide and Porath, 1966).  Today, antibody engineering is a nascent science, with 
applications to a wide variety of diagnostics and primary treatments.  As a result, the IgG 
molecule is probably the most studied of all proteins worldwide (Kohler and Milstein, 1975; 
Padlan, 1994).   
 
At the beginning of the journey into antibody testing and for most of the time since, serum has 
had the primary role as diagnostic specimen.  However, greater understanding of IgG corporal 
distribution and functionality has allowed other body fluids to become practical and affordable 
alternatives (Prickett et al., 2008; Rotolo et al., 2017).  Saliva, better termed "oral fluids", was 
first used in livestock diagnostics beginning in the latter 1990’s (Smith et al., 2003; Wills et al., 
1997).  The simultaneous appearance of PRRSV antibodies in serum and swine oral fluids 
supported the importance of oral fluid in swine diseases surveillance in commercial herds 
(Kittawornrat et al., 2013; Kuiek et al., 2015; Ramirez et al., 2012).  However, the oral fluid 
specimens often contain feed, feces, and environmental contaminants that may affect liquid 
handling and test performance in the laboratory.   
 
The approach to clarify swine oral fluids evaluated in this research was based on an ancient 
technology that is still widely used in water treatment, food and beverage industries, and cutting-
edge medical technologies (Alves and Mano, 2008; Angelakis and Zheng, 2015; Rinaudo, 2006; 
Zeng, et al 2008).  The analyses of PRRSV IgG stability in swine oral fluid samples undergoing 
chemical treatments showed that it is possible to improve their innate characteristics, i.e., quickly 
and inexpensively remove suspended particulates, without affecting ELISA antibody responses.  
47 
 
 
 
 
However, the basic information about the physicochemical processes and main external factors 
that affect humans IgG stability is not sufficient, and information of interspecies and subclasses 
differences among IgGs is needed to better understand specific interactions of chemicals-
antibody and its impact in diagnostics.  Future efforts should include the evaluation of other 
coagulants and/or combinations of coagulants, e.g., chitosan in combination with others.  In 
addition, the feasibility of using similar clarification approaches with other “polluted” diagnostic 
specimens like feces, colostrum or milk.  
 
Sample clarification represents an affordable approach for the improvement of oral fluids, and 
probably other diagnostic specimens (Henao-Diaz et al., 2017).  More broadly, further 
development of cost-effective, rapid clean-up technologies will expand our repertoire of 
diagnostic specimens, improve the sample-handling characteristics of these specimens in high-
throughput laboratories, and create greater opportunities for the efficient collection of 
surveillance data.  In summary, the research described in this thesis represents initial attempts at 
improving the characteristics of oral fluid as a diagnostic specimen, but likewise represents the 
beginning of a new line of research in the improvement, development, and/or expansion of 
veterinary diagnostic specimens.  
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